Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
Journal of Multidisciplinary Healthcare|December 7, 2018
Involving "authentic" cancer patients, their caregivers, and multidisciplinary professionals in a quality improvement trajectory in a hospital cancer pathway: a study protocolInge Melchior, Albine Moser, Marja Y Veenstra, et al.Health Expectations : an International Journal of Public Participation in Health Care and Health Policy|January 13, 2021
Improving the experience of older people with colorectal and breast cancer in patient-centred cancer care pathways using experience-based co-designAlbine Moser, Inge Melchior, Marja Veenstra, et al.Journal of Multidisciplinary Healthcare|September 10, 2024
Tools and Strategies to Integrate Multi-Domain Information for Personalized Decision-Making in Oncological Care Pathways: A Scoping ReviewThanee M Uittenhout, Jesse Jansen, Kon-Siong Jie, et al.The Lancet. Haematology|November 26, 2020
Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trialMurielle Roussel, Philippe Moreau, Benjamin Hebraud, et al.Haematologica|September 3, 2013
Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trialChristof Scheid, Pieter Sonneveld, Ingo G H Schmidt-Wolf, et al.The Lancet. Oncology|June 18, 2024
Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trialPhilippe Moreau, Cyrille Hulin, Aurore Perrot, et al.The Lancet. Oncology|September 16, 2021
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trialPhilippe Moreau, Cyrille Hulin, Aurore Perrot, et al.Lancet (London, England)|June 8, 2019
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 studyPhilippe Moreau, Michel Attal, Cyrille Hulin, et al.Pageof 1